Danaher Corporation $DHR Shares Sold by Redwood Investments LLC

Key Points

• Redwood Investments LLC sold 84.1% of its holdings in Danaher Corporation during the 1st quarter, reducing its ownership to 4,700 shares worth approximately $964,000.
• Institutional investors now own 79.05% of Danaher’s stock, with GHP Investment Advisors increasing its stake by 396.0%.
• Danaher reported earnings of $1.80 per share for the most recent quarter, exceeding estimates, and projects 2025 EPS guidance of 7.700-7.800.

Redwood Investments LLC cut its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 84.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,700 shares of the conglomerate's stock after selling 24,834 shares during the quarter. Redwood Investments LLC's holdings in Danaher were worth $964,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of DHR. Bank Pictet & Cie Europe AG grew its holdings in shares of Danaher by 22.8% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 192,731 shares of the conglomerate's stock worth $44,241,000 after purchasing an additional 35,730 shares during the period. Focus Partners Wealth grew its holdings in shares of Danaher by 19.8% during the 4th quarter. Focus Partners Wealth now owns 177,596 shares of the conglomerate's stock worth $40,818,000 after purchasing an additional 29,409 shares during the period. Gotham Asset Management LLC lifted its stake in Danaher by 29.0% during the 4th quarter. Gotham Asset Management LLC now owns 57,043 shares of the conglomerate's stock worth $13,094,000 after acquiring an additional 12,828 shares in the last quarter. Humankind Investments LLC lifted its stake in Danaher by 21.5% during the 4th quarter. Humankind Investments LLC now owns 3,952 shares of the conglomerate's stock worth $907,000 after acquiring an additional 700 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its stake in Danaher by 1.3% during the 4th quarter. Janus Henderson Group PLC now owns 3,933,078 shares of the conglomerate's stock worth $902,846,000 after acquiring an additional 50,283 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

DHR has been the topic of several research reports. Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price on the stock in a research note on Friday, July 11th. Robert W. Baird increased their target price on Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a research note on Friday, July 18th. Deutsche Bank Aktiengesellschaft decreased their target price on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Royal Bank Of Canada set a $241.00 target price on Danaher in a research note on Tuesday, September 2nd. Finally, Wells Fargo & Company decreased their target price on Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 23rd. Seventeen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $246.35.

Insider Buying and Selling

In other Danaher news, Director Teri List sold 2,778 shares of Danaher stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director owned 20,751 shares of the company's stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 11.10% of the stock is currently owned by company insiders.

Danaher Stock Up 1.4%

DHR stock traded up $2.64 during trading on Thursday, hitting $195.23. 3,425,999 shares of the company's stock were exchanged, compared to its average volume of 4,141,844. The business has a 50-day moving average price of $201.62 and a two-hundred day moving average price of $199.15. The stock has a market capitalization of $139.79 billion, a price-to-earnings ratio of 41.54, a PEG ratio of 2.71 and a beta of 0.75. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.90. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.16. The firm had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The firm's revenue was up 3.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, equities research analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be paid a dividend of $0.32 per share. The ex-dividend date is Friday, September 26th. This represents a $1.28 annualized dividend and a yield of 0.7%. Danaher's payout ratio is presently 27.23%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.